Market Outlook
The global Recombinant Influenza Vaccine market size was valued at USD 109.9 million in 2022 and is forecast to a readjusted size of USD 190 million by 2029 with a CAGR of 8.1% during review period.
Recombinant technology plays an important role in the preparation of influenza vaccines. It allows scientists to create and express specific influenza virus proteins through genetic engineering to prepare influenza vaccines. This approach typically involves inserting the genetic sequence of the influenza virus into an expression system, enabling it to produce viral antigen proteins, and then using these proteins to prepare a vaccine.
A significant driver in the Influenza Vaccine market is the growing awareness of the importance of vaccination in preventing seasonal and pandemic influenza outbreaks. As healthcare organizations and governments worldwide promote vaccination as a crucial public health measure, there is an increasing demand for influenza vaccines. Additionally, advances in vaccine research and development, including the production of more effective and broader-spectrum vaccines, are driving market growth. One of the key challenges in this market is the need for frequent vaccine updates to match evolving influenza strains. The virus undergoes genetic changes, requiring annual adjustments to vaccine formulations. This presents logistical challenges for manufacturers in terms of timely production and distribution. Vaccine hesitancy and misinformation also pose challenges by impacting vaccination rates and public perception. Lastly, ensuring equitable access to vaccines, especially in low-income and underserved populations, remains a persistent challenge in the fight against influenza.
The Global Info Research report includes an overview of the development of the Recombinant Influenza Vaccine industry chain, the market status of Public Sector (Vial, Prefilled), Private Sector (Vial, Prefilled), and key enterprises in developed and developing market, and analyzed the cutting-edge technology, patent, hot applications and market trends of Recombinant Influenza Vaccine.
Regionally, the report analyzes the Recombinant Influenza Vaccine markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Recombinant Influenza Vaccine market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Recombinant Influenza Vaccine market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Recombinant Influenza Vaccine industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Vial, Prefilled).
Industry Analysis: Report analyze the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Recombinant Influenza Vaccine market.
Regional Analysis: The report involves examining the Recombinant Influenza Vaccine market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behavior to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Recombinant Influenza Vaccine market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Recombinant Influenza Vaccine:
Company Analysis: Report covers individual Recombinant Influenza Vaccine manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behavior, preferences, and attitudes towards Recombinant Influenza Vaccine This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Public Sector, Private Sector).
Technology Analysis: Report covers specific technologies relevant to Recombinant Influenza Vaccine. It assesses the current state, advancements, and potential future developments in Recombinant Influenza Vaccine areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Recombinant Influenza Vaccine market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Key Market Players
Sanofi
Segmentation By Type
Vial
Prefilled
Segmentation By Application
Public Sector
Private Sector
Segmentation By Region
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Market SWOT Analysis
What are the strengths of the Recombinant Influenza Vaccine Market in 2025?
The recombinant influenza vaccine market in 2025 benefits from advanced technology, providing faster production times and higher safety profiles compared to traditional vaccines. These vaccines also offer the potential for broader protection, including against rapidly mutating strains.
What are the weaknesses within the recombinant influenza vaccine market?
High production costs and the complexity of manufacturing recombinant vaccines pose significant challenges. Additionally, public reluctance and misinformation about new vaccine technologies could slow market penetration, especially in regions with low vaccine adoption rates.
What opportunities can shape the future of this market?
Continued advancements in biotechnology could lead to more affordable and efficient vaccine production methods. Additionally, partnerships between vaccine manufacturers and healthcare systems, as well as government support, could enhance global accessibility, opening doors to new markets, particularly in developing countries.
What threats could impact the recombinant influenza vaccine market?
The ongoing competition from traditional flu vaccines, particularly those that are less expensive, may hinder market expansion. Additionally, the possibility of emerging infectious diseases and vaccine hesitancy could lead to fluctuations in demand and hinder the growth of the recombinant vaccine market.
Market PESTEL Analysis
What political factors will influence the recombinant influenza vaccine market in 2025?
Government policies regarding vaccine distribution, public health initiatives, and funding for research and development will significantly impact the recombinant influenza vaccine market. Additionally, political support for vaccine mandates and public health programs will drive demand.
How will economic factors affect this market?
Economic factors, such as healthcare budgets and disposable income, will play a role in market growth. In wealthier countries, higher spending on healthcare will increase demand for advanced vaccines. In contrast, lower-income regions may face challenges in affording these more expensive vaccines.
What social factors are relevant to the recombinant influenza vaccine market?
Public awareness of the benefits of flu vaccination and the increasing acceptance of recombinant vaccine technology will boost market growth. However, vaccine hesitancy and misinformation could limit adoption, especially in areas with less trust in healthcare systems.
How do technological factors impact the market?
Technological advancements in biotechnology, such as faster vaccine production and more precise targeting of flu strains, will enhance the efficacy and appeal of recombinant influenza vaccines. Ongoing innovation in manufacturing processes will help reduce costs and improve accessibility.
What environmental factors are relevant to the recombinant influenza vaccine market?
Environmental sustainability concerns, such as the carbon footprint of vaccine production, may become increasingly important. Manufacturers will need to consider greener production methods and packaging solutions to meet global environmental standards.
How will legal factors influence the recombinant influenza vaccine market?
Regulatory frameworks governing vaccine approval and distribution will impact market growth. Stringent regulations in different regions could delay vaccine availability, while intellectual property laws around recombinant technology may affect competition and pricing.
Market SIPOC Analysis
Who are the suppliers in the recombinant influenza vaccine market in 2025?
Suppliers include biotechnology companies, raw material providers (like proteins, adjuvants, and culture media), and manufacturers of specialized equipment for recombinant vaccine production.
What are the inputs required for recombinant influenza vaccine production?
Inputs include the necessary biological materials, such as viral genes for recombinant strains, advanced bioreactors for vaccine production, and skilled workforce for research, development, and quality control.
What processes are involved in the recombinant influenza vaccine market?
Processes include gene selection, recombinant DNA technology, vaccine production through fermentation or cell culture, purification, formulation, clinical trials, regulatory approvals, and mass distribution.
Who are the customers in the recombinant influenza vaccine market?
Customers include governments, healthcare providers, hospitals, clinics, and pharmaceutical companies, as well as individuals receiving vaccinations, particularly in high-risk groups such as the elderly and immunocompromised.
What are the outputs or results of recombinant influenza vaccine production?
Outputs include the final recombinant influenza vaccines, packaging, and distribution for public health programs, alongside scientific research advancements in vaccine technology and disease prevention.
Market Porter's Five Forces
How intense is the threat of new entrants in the recombinant influenza vaccine market in 2025?
The threat of new entrants is moderate. High barriers to entry, such as the need for advanced biotechnology, regulatory approvals, and significant capital investment, make it challenging for new players to enter. However, emerging technologies may enable new competitors in the future.
What is the bargaining power of suppliers in the recombinant influenza vaccine market?
The bargaining power of suppliers is relatively high. The market relies on specialized raw materials and technologies, such as viral strains, adjuvants, and biotechnological platforms, which are often limited to a few key suppliers.
What is the bargaining power of buyers in the recombinant influenza vaccine market?
The bargaining power of buyers is low to moderate. While individual consumers have limited influence, large buyers like governments and healthcare systems have some leverage to negotiate prices and contract terms. However, the essential nature of vaccines reduces buyer power.
How intense is the rivalry among existing competitors in the recombinant influenza vaccine market?
Rivalry is moderate. The recombinant influenza vaccine market is dominated by a few large players, with high innovation requirements and significant R&D investment. While competition is fierce, the specialized nature of these vaccines reduces direct competition among many firms.
What is the threat of substitute products in the recombinant influenza vaccine market?
The threat of substitutes is low. Currently, no other vaccine technology offers the same efficacy, speed of production, and flexibility as recombinant vaccines. Traditional flu vaccines are still prevalent, but recombinant vaccines provide distinct advantages, reducing the risk of substitution.
Market Upstream Analysis
What are the key raw materials needed for the recombinant influenza vaccine market in 2025?
Key raw materials include genetic material for recombinant strains, adjuvants, cell culture media, proteins, and bioreactor components. These materials are essential for the production and stabilization of the vaccines.
Who are the main suppliers of these raw materials?
Main suppliers are biotechnology companies that provide genetic sequences for recombinant technology, pharmaceutical companies that supply adjuvants and culture media, and specialized manufacturers of bioreactors and purification equipment.
How does technology impact the upstream process in recombinant influenza vaccine production?
Advancements in biotechnology, such as gene sequencing, CRISPR technology, and cell culture systems, play a crucial role in improving the efficiency, scalability, and cost-effectiveness of vaccine production. This helps meet global demand and accelerates the production timeline.
What are the challenges faced by upstream suppliers in this market?
Challenges include the high cost and complexity of producing high-quality raw materials, regulatory compliance for biotechnological products, and maintaining a reliable supply chain for critical components. There are also risks related to supply shortages or disruptions in production.
How does the regulatory environment affect upstream operations in the recombinant influenza vaccine market?
The regulatory environment imposes stringent requirements on the production of raw materials, particularly with regards to safety and quality control. Suppliers must comply with standards from organizations such as the FDA or EMA, which can increase operational costs and time to market.
Market Midstream Analysis
What are the key processes involved in the midstream stage of the recombinant influenza vaccine market?
Key processes include the genetic engineering of the virus strain, vaccine production through cell culture or fermentation, purification, formulation, and quality control. These processes ensure that the vaccine is safe, effective, and ready for distribution.
How does technology influence the midstream stage of recombinant influenza vaccine production?
Technological advancements in genetic engineering, cell culture methods, and purification techniques improve the efficiency and scalability of vaccine production. These innovations help to reduce production costs and time, while also enhancing the consistency and quality of the final product.
What are the main challenges faced during the midstream process?
Challenges include maintaining the sterility and integrity of the production environment, ensuring consistent vaccine yield, and meeting regulatory requirements for quality control. Any disruption in the production process can delay time to market and impact vaccine availability.
How do regulatory requirements impact the midstream process?
Regulatory requirements dictate strict guidelines for manufacturing, including Good Manufacturing Practices (GMP), safety testing, and documentation. These regulations ensure the vaccine's safety and efficacy but can also slow down production and increase costs.
What role do partnerships play in the midstream process of recombinant influenza vaccine production?
Partnerships between vaccine developers, contract manufacturers, and research institutions play a critical role in enhancing production capacity, sharing expertise, and optimizing production processes. These collaborations help meet the growing demand for recombinant influenza vaccines.
Market Downstream Analysis
What are the key activities in the downstream stage of the recombinant influenza vaccine market?
Key activities include packaging, distribution, and administration of the vaccines to healthcare providers, hospitals, clinics, and vaccination centers. Post-production activities also involve marketing, regulatory approval for use in different regions, and monitoring vaccine safety.
How does the distribution network impact the downstream process?
A robust and efficient distribution network is crucial for ensuring timely delivery of vaccines to global markets, especially in regions with limited healthcare infrastructure. Cold chain logistics and transportation security are key considerations in maintaining vaccine potency and effectiveness.
What challenges are faced during the downstream stage?
Challenges include logistical hurdles such as maintaining the cold chain during transportation, ensuring equitable distribution in low-income regions, and addressing vaccine hesitancy in various populations. Additionally, regulatory barriers across different regions can delay vaccine availability.
How do market dynamics and competition influence the downstream process?
Market dynamics and competition impact pricing strategies, demand forecasts, and marketing efforts. Strong competition from traditional flu vaccines may influence how recombinant vaccines are positioned and adopted by healthcare providers and patients.
What role do healthcare providers play in the downstream process?
Healthcare providers play a critical role in administering the vaccines, educating patients about their benefits, and ensuring proper documentation and reporting. Their involvement in the vaccination process directly affects vaccine uptake and public health outcomes.
Chapter 1, to describe Recombinant Influenza Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Recombinant Influenza Vaccine, with price, sales, revenue and global market share of Recombinant Influenza Vaccine from 2018 to 2023.
Chapter 3, the Recombinant Influenza Vaccine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Recombinant Influenza Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Recombinant Influenza Vaccine market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Recombinant Influenza Vaccine.
Chapter 14 and 15, to describe Recombinant Influenza Vaccine sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Recombinant Influenza Vaccine
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Recombinant Influenza Vaccine Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Vial
1.3.3 Prefilled
1.4 Market Analysis by Application
1.4.1 Overview: Global Recombinant Influenza Vaccine Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Public Sector
1.4.3 Private Sector
1.5 Global Recombinant Influenza Vaccine Market Size & Forecast
1.5.1 Global Recombinant Influenza Vaccine Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Recombinant Influenza Vaccine Sales Quantity (2018-2029)
1.5.3 Global Recombinant Influenza Vaccine Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Recombinant Influenza Vaccine Product and Services
2.1.4 Sanofi Recombinant Influenza Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Sanofi Recent Developments/Updates
3 Competitive Environment: Recombinant Influenza Vaccine by Manufacturer
3.1 Global Recombinant Influenza Vaccine Sales Quantity by Manufacturer (2018-2023)
3.2 Global Recombinant Influenza Vaccine Revenue by Manufacturer (2018-2023)
3.3 Global Recombinant Influenza Vaccine Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Recombinant Influenza Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Recombinant Influenza Vaccine Manufacturer Market Share in 2022
3.4.2 Top 6 Recombinant Influenza Vaccine Manufacturer Market Share in 2022
3.5 Recombinant Influenza Vaccine Market: Overall Company Footprint Analysis
3.5.1 Recombinant Influenza Vaccine Market: Region Footprint
3.5.2 Recombinant Influenza Vaccine Market: Company Product Type Footprint
3.5.3 Recombinant Influenza Vaccine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Recombinant Influenza Vaccine Market Size by Region
4.1.1 Global Recombinant Influenza Vaccine Sales Quantity by Region (2018-2029)
4.1.2 Global Recombinant Influenza Vaccine Consumption Value by Region (2018-2029)
4.1.3 Global Recombinant Influenza Vaccine Average Price by Region (2018-2029)
4.2 North America Recombinant Influenza Vaccine Consumption Value (2018-2029)
4.3 Europe Recombinant Influenza Vaccine Consumption Value (2018-2029)
4.4 Asia-Pacific Recombinant Influenza Vaccine Consumption Value (2018-2029)
4.5 South America Recombinant Influenza Vaccine Consumption Value (2018-2029)
4.6 Middle East and Africa Recombinant Influenza Vaccine Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Recombinant Influenza Vaccine Sales Quantity by Type (2018-2029)
5.2 Global Recombinant Influenza Vaccine Consumption Value by Type (2018-2029)
5.3 Global Recombinant Influenza Vaccine Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Recombinant Influenza Vaccine Sales Quantity by Application (2018-2029)
6.2 Global Recombinant Influenza Vaccine Consumption Value by Application (2018-2029)
6.3 Global Recombinant Influenza Vaccine Average Price by Application (2018-2029)
7 North America
7.1 North America Recombinant Influenza Vaccine Sales Quantity by Type (2018-2029)
7.2 North America Recombinant Influenza Vaccine Sales Quantity by Application (2018-2029)
7.3 North America Recombinant Influenza Vaccine Market Size by Country
7.3.1 North America Recombinant Influenza Vaccine Sales Quantity by Country (2018-2029)
7.3.2 North America Recombinant Influenza Vaccine Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Recombinant Influenza Vaccine Sales Quantity by Type (2018-2029)
8.2 Europe Recombinant Influenza Vaccine Sales Quantity by Application (2018-2029)
8.3 Europe Recombinant Influenza Vaccine Market Size by Country
8.3.1 Europe Recombinant Influenza Vaccine Sales Quantity by Country (2018-2029)
8.3.2 Europe Recombinant Influenza Vaccine Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Recombinant Influenza Vaccine Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Recombinant Influenza Vaccine Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Recombinant Influenza Vaccine Market Size by Region
9.3.1 Asia-Pacific Recombinant Influenza Vaccine Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Recombinant Influenza Vaccine Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Recombinant Influenza Vaccine Sales Quantity by Type (2018-2029)
10.2 South America Recombinant Influenza Vaccine Sales Quantity by Application (2018-2029)
10.3 South America Recombinant Influenza Vaccine Market Size by Country
10.3.1 South America Recombinant Influenza Vaccine Sales Quantity by Country (2018-2029)
10.3.2 South America Recombinant Influenza Vaccine Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Recombinant Influenza Vaccine Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Recombinant Influenza Vaccine Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Recombinant Influenza Vaccine Market Size by Country
11.3.1 Middle East & Africa Recombinant Influenza Vaccine Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Recombinant Influenza Vaccine Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Recombinant Influenza Vaccine Market Drivers
12.2 Recombinant Influenza Vaccine Market Restraints
12.3 Recombinant Influenza Vaccine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Recombinant Influenza Vaccine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Recombinant Influenza Vaccine
13.3 Recombinant Influenza Vaccine Production Process
13.4 Recombinant Influenza Vaccine Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Recombinant Influenza Vaccine Typical Distributors
14.3 Recombinant Influenza Vaccine Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
List of Tables
Table 1. Global Recombinant Influenza Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Recombinant Influenza Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Sanofi Basic Information, Manufacturing Base and Competitors
Table 4. Sanofi Major Business
Table 5. Sanofi Recombinant Influenza Vaccine Product and Services
Table 6. Sanofi Recombinant Influenza Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Sanofi Recent Developments/Updates
Table 8. Global Recombinant Influenza Vaccine Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 9. Global Recombinant Influenza Vaccine Revenue by Manufacturer (2018-2023) & (USD Million)
Table 10. Global Recombinant Influenza Vaccine Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 11. Market Position of Manufacturers in Recombinant Influenza Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 12. Head Office and Recombinant Influenza Vaccine Production Site of Key Manufacturer
Table 13. Recombinant Influenza Vaccine Market: Company Product Type Footprint
Table 14. Recombinant Influenza Vaccine Market: Company Product Application Footprint
Table 15. Recombinant Influenza Vaccine New Market Entrants and Barriers to Market Entry
Table 16. Recombinant Influenza Vaccine Mergers, Acquisition, Agreements, and Collaborations
Table 17. Global Recombinant Influenza Vaccine Sales Quantity by Region (2018-2023) & (K Units)
Table 18. Global Recombinant Influenza Vaccine Sales Quantity by Region (2024-2029) & (K Units)
Table 19. Global Recombinant Influenza Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 20. Global Recombinant Influenza Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 21. Global Recombinant Influenza Vaccine Average Price by Region (2018-2023) & (US$/Unit)
Table 22. Global Recombinant Influenza Vaccine Average Price by Region (2024-2029) & (US$/Unit)
Table 23. Global Recombinant Influenza Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 24. Global Recombinant Influenza Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 25. Global Recombinant Influenza Vaccine Consumption Value by Type (2018-2023) & (USD Million)
Table 26. Global Recombinant Influenza Vaccine Consumption Value by Type (2024-2029) & (USD Million)
Table 27. Global Recombinant Influenza Vaccine Average Price by Type (2018-2023) & (US$/Unit)
Table 28. Global Recombinant Influenza Vaccine Average Price by Type (2024-2029) & (US$/Unit)
Table 29. Global Recombinant Influenza Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 30. Global Recombinant Influenza Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 31. Global Recombinant Influenza Vaccine Consumption Value by Application (2018-2023) & (USD Million)
Table 32. Global Recombinant Influenza Vaccine Consumption Value by Application (2024-2029) & (USD Million)
Table 33. Global Recombinant Influenza Vaccine Average Price by Application (2018-2023) & (US$/Unit)
Table 34. Global Recombinant Influenza Vaccine Average Price by Application (2024-2029) & (US$/Unit)
Table 35. North America Recombinant Influenza Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 36. North America Recombinant Influenza Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 37. North America Recombinant Influenza Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 38. North America Recombinant Influenza Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 39. North America Recombinant Influenza Vaccine Sales Quantity by Country (2018-2023) & (K Units)
Table 40. North America Recombinant Influenza Vaccine Sales Quantity by Country (2024-2029) & (K Units)
Table 41. North America Recombinant Influenza Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 42. North America Recombinant Influenza Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 43. Europe Recombinant Influenza Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 44. Europe Recombinant Influenza Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 45. Europe Recombinant Influenza Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 46. Europe Recombinant Influenza Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 47. Europe Recombinant Influenza Vaccine Sales Quantity by Country (2018-2023) & (K Units)
Table 48. Europe Recombinant Influenza Vaccine Sales Quantity by Country (2024-2029) & (K Units)
Table 49. Europe Recombinant Influenza Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 50. Europe Recombinant Influenza Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 51. Asia-Pacific Recombinant Influenza Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 52. Asia-Pacific Recombinant Influenza Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 53. Asia-Pacific Recombinant Influenza Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 54. Asia-Pacific Recombinant Influenza Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 55. Asia-Pacific Recombinant Influenza Vaccine Sales Quantity by Region (2018-2023) & (K Units)
Table 56. Asia-Pacific Recombinant Influenza Vaccine Sales Quantity by Region (2024-2029) & (K Units)
Table 57. Asia-Pacific Recombinant Influenza Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 58. Asia-Pacific Recombinant Influenza Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 59. South America Recombinant Influenza Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 60. South America Recombinant Influenza Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 61. South America Recombinant Influenza Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 62. South America Recombinant Influenza Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 63. South America Recombinant Influenza Vaccine Sales Quantity by Country (2018-2023) & (K Units)
Table 64. South America Recombinant Influenza Vaccine Sales Quantity by Country (2024-2029) & (K Units)
Table 65. South America Recombinant Influenza Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 66. South America Recombinant Influenza Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 67. Middle East & Africa Recombinant Influenza Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 68. Middle East & Africa Recombinant Influenza Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 69. Middle East & Africa Recombinant Influenza Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 70. Middle East & Africa Recombinant Influenza Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 71. Middle East & Africa Recombinant Influenza Vaccine Sales Quantity by Region (2018-2023) & (K Units)
Table 72. Middle East & Africa Recombinant Influenza Vaccine Sales Quantity by Region (2024-2029) & (K Units)
Table 73. Middle East & Africa Recombinant Influenza Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 74. Middle East & Africa Recombinant Influenza Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 75. Recombinant Influenza Vaccine Raw Material
Table 76. Key Manufacturers of Recombinant Influenza Vaccine Raw Materials
Table 77. Recombinant Influenza Vaccine Typical Distributors
Table 78. Recombinant Influenza Vaccine Typical Customers
List of Figures
Figure 1. Recombinant Influenza Vaccine Picture
Figure 2. Global Recombinant Influenza Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Recombinant Influenza Vaccine Consumption Value Market Share by Type in 2022
Figure 4. Vial Examples
Figure 5. Prefilled Examples
Figure 6. Global Recombinant Influenza Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global Recombinant Influenza Vaccine Consumption Value Market Share by Application in 2022
Figure 8. Public Sector Examples
Figure 9. Private Sector Examples
Figure 10. Global Recombinant Influenza Vaccine Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 11. Global Recombinant Influenza Vaccine Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 12. Global Recombinant Influenza Vaccine Sales Quantity (2018-2029) & (K Units)
Figure 13. Global Recombinant Influenza Vaccine Average Price (2018-2029) & (US$/Unit)
Figure 14. Global Recombinant Influenza Vaccine Sales Quantity Market Share by Manufacturer in 2022
Figure 15. Global Recombinant Influenza Vaccine Consumption Value Market Share by Manufacturer in 2022
Figure 16. Producer Shipments of Recombinant Influenza Vaccine by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 17. Top 3 Recombinant Influenza Vaccine Manufacturer (Consumption Value) Market Share in 2022
Figure 18. Top 6 Recombinant Influenza Vaccine Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Global Recombinant Influenza Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 20. Global Recombinant Influenza Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 21. North America Recombinant Influenza Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 22. Europe Recombinant Influenza Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 23. Asia-Pacific Recombinant Influenza Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 24. South America Recombinant Influenza Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 25. Middle East & Africa Recombinant Influenza Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 26. Global Recombinant Influenza Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 27. Global Recombinant Influenza Vaccine Consumption Value Market Share by Type (2018-2029)
Figure 28. Global Recombinant Influenza Vaccine Average Price by Type (2018-2029) & (US$/Unit)
Figure 29. Global Recombinant Influenza Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 30. Global Recombinant Influenza Vaccine Consumption Value Market Share by Application (2018-2029)
Figure 31. Global Recombinant Influenza Vaccine Average Price by Application (2018-2029) & (US$/Unit)
Figure 32. North America Recombinant Influenza Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 33. North America Recombinant Influenza Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 34. North America Recombinant Influenza Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 35. North America Recombinant Influenza Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 36. United States Recombinant Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 37. Canada Recombinant Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Mexico Recombinant Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Europe Recombinant Influenza Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 40. Europe Recombinant Influenza Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 41. Europe Recombinant Influenza Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 42. Europe Recombinant Influenza Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 43. Germany Recombinant Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 44. France Recombinant Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. United Kingdom Recombinant Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. Russia Recombinant Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Italy Recombinant Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Asia-Pacific Recombinant Influenza Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 49. Asia-Pacific Recombinant Influenza Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 50. Asia-Pacific Recombinant Influenza Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 51. Asia-Pacific Recombinant Influenza Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 52. China Recombinant Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. Japan Recombinant Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Korea Recombinant Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. India Recombinant Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Southeast Asia Recombinant Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Australia Recombinant Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. South America Recombinant Influenza Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 59. South America Recombinant Influenza Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 60. South America Recombinant Influenza Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 61. South America Recombinant Influenza Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 62. Brazil Recombinant Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. Argentina Recombinant Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Middle East & Africa Recombinant Influenza Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 65. Middle East & Africa Recombinant Influenza Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 66. Middle East & Africa Recombinant Influenza Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 67. Middle East & Africa Recombinant Influenza Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 68. Turkey Recombinant Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 69. Egypt Recombinant Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Saudi Arabia Recombinant Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. South Africa Recombinant Influenza Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Recombinant Influenza Vaccine Market Drivers
Figure 73. Recombinant Influenza Vaccine Market Restraints
Figure 74. Recombinant Influenza Vaccine Market Trends
Figure 75. Porters Five Forces Analysis
Figure 76. Manufacturing Cost Structure Analysis of Recombinant Influenza Vaccine in 2022
Figure 77. Manufacturing Process Analysis of Recombinant Influenza Vaccine
Figure 78. Recombinant Influenza Vaccine Industrial Chain
Figure 79. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 80. Direct Channel Pros & Cons
Figure 81. Indirect Channel Pros & Cons
Figure 82. Methodology
Figure 83. Research Process and Data Source
